Hepatic Safety Of Biogen Idec’s Zinbryta Under Close Scrutiny In EU
Executive Summary
The EU review of Biogen Idec’s MS drug Zinbryta is continuing as a special group at the European Medicines Agency prepares to discuss a list of questions regarding the product’s hepatic safety profile. The EMA has until the end of November to give its views on the product’s future.
You may also be interested in...
The Zinbryta Withdrawal And The Limits Of US FDA’s Proactive Communication
FDA is getting justifiably high marks for its efforts to accelerate drug development, and the proactive communication approach of Commissioner Gottlieb is a big part of that dynamic. But a drug safety withdrawal could be a sign of trouble ahead, if the perception takes hold that Europe is more proactive when it comes to patient safety.
Zinbryta Global Withdrawal Driven In Part By Difficulty Of Safety Assessment
EMA safety investigation pushes decision as AbbVie, Biogen acknowledge 'characterizing the evolving benefit/risk profile … will not be possible going forward given the limited number of patients being treated.'
Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.